Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 15 January 2026 - 16 January 2026

Eli Lilly stock price edges higher as FDA timeline for obesity pill comes into focus

Eli Lilly stock price edges higher as FDA timeline for obesity pill comes into focus

New York, Jan 16, 2026, 11:00 EST — Regular session Eli Lilly shares rose 0.3% to $1,036.46 on Friday morning, after touching as low as $1,019, as investors weighed an updated U.S. regulatory timeline for the company’s experimental obesity pill. (Reuters) The stock has become a proxy for how fast the next wave of weight-loss drugs can move from injections…
16 January 2026
··
PainReform PRFX stock jumps in premarket after company rebrands as PRF Technologies

PainReform PRFX stock jumps in premarket after company rebrands as PRF Technologies

NEW YORK, Jan 16, 2026, 09:12 EST — Premarket PainReform Ltd shares rose in premarket trading on Friday following the company’s announcement that it has rebranded as PRF Technologies Ltd. The microcap firm said the new name signals an expansion beyond its initial focus on pain therapy. The name change is significant because PainReform was mainly evaluated based on a…
16 January 2026
··
Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed

Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed

New York, January 16, 2026, 05:24 EST — Premarket Eli Lilly and Co shares slipped 3.8% in premarket trading Friday, following a wave of regulatory and legal news around its obesity drugs late last week. The stock last traded at $1,032.97. These shifts are crucial since Lilly’s valuation now hinges on the outlook for its upcoming obesity drugs and how…
16 January 2026
···
Eli Lilly stock slides after FDA pushes obesity pill decision to April 10

Eli Lilly stock slides after FDA pushes obesity pill decision to April 10

New York, Jan 15, 2026, 16:43 (EST) — After-hours Eli Lilly and Co shares dropped 3.8% to $1,032.97 in after-hours trading Thursday after Reuters reported the FDA is now aiming for an April 10 decision on Lilly’s experimental obesity drug, orforglipron. The report also revealed delays in other drugs under a new fast-track review program, following safety and efficacy concerns…
15 January 2026
···
Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

New York, Jan 15, 2026, 13:24 EST — Regular session Pfizer shares edged up roughly 0.3% to $25.67 on Thursday, finding footing after a volatile start to the year. Investors mulled over renewed discussions on U.S. vaccine policy alongside Pfizer’s growth strategy. The stock fluctuated between $25.26 and $25.67, with about 22.3 million shares changing hands. Why it matters now:…
15 January 2026
··
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

New York, Jan 15, 2026, 11:16 EST — Regular session. Pfizer Inc. shares fell 0.6% to $25.42 in late-morning trading on Thursday, extending a choppy start to the year for the drugmaker’s stock. The stock has struggled to find a clear driver since Pfizer warned in December that 2026 would likely start “bumpy,” with lower COVID-related sales, price cuts tied…
15 January 2026
··
AbbVie stock slides 2% as obesity push takes center stage at JPM conference

AbbVie stock slides 2% as obesity push takes center stage at JPM conference

New York, January 15, 2026, 12:11 (EST) — Regular session AbbVie shares dropped 2.1% to $217.13 Thursday following the company’s expanded plans for obesity treatments announced at the J.P. Morgan Healthcare Conference. This matters since AbbVie is hunting for its next major growth driver, as its aging blockbuster Humira grapples with increased competition from biosimilars. Investors have shown they’re eager…
15 January 2026
··
Johnson & Johnson stock slips as Tecvayli trial data lands ahead of earnings week

Johnson & Johnson stock slips as Tecvayli trial data lands ahead of earnings week

New York, Jan 15, 2026, 11:01 ET — Regular session Johnson & Johnson shares dipped Thursday following fresh late-stage data release for its Tecvayli cancer drug, with investors also bracing for next week’s earnings report. This update is crucial as Johnson & Johnson aims to expand the footprint of its newer drugs while shielding established products from pricing cuts and…
15 January 2026
····
GSK stock rises as pipeline talk hits JPM conference, with Feb. 4 earnings in focus

GSK stock rises as pipeline talk hits JPM conference, with Feb. 4 earnings in focus

New York, January 15, 2026, 02:30 EST — The market has closed. GSK plc’s shares traded in the U.S. climbed 1.8% on Wednesday, closing at $50.79. The stock remains in the spotlight heading into Thursday’s session. U.S. markets were closed overnight, leaving investors to watch for follow-through in premarket trading and in London after a week packed with conference headlines…
15 January 2026
····
Merck stock rises as $70 billion growth target sharpens focus ahead of Feb. 3 earnings

Merck stock rises as $70 billion growth target sharpens focus ahead of Feb. 3 earnings

New York, Jan 14, 2026, 20:15 EST — Market closed Merck & Co (Merck & Company, Inc., MRK) shares closed Wednesday up 2.54% at $111.01, rebounding from a short dip and holding close to recent peaks ahead of Thursday’s trading. This move is crucial as Merck works to reshape the conversation about what will follow Keytruda, its top-selling drug, once…
15 January 2026
····
AbbVie stock in focus after hours as it eyes obesity market — what to watch next

AbbVie stock in focus after hours as it eyes obesity market — what to watch next

New York, Jan 14, 2026, 19:30 EST — After-hours AbbVie Inc’s shares climbed roughly 0.5% to $221.89 in after-hours trading Wednesday, following executives’ announcement to expand the company’s footprint in obesity treatments. During the regular session, the stock fluctuated between $217.84 and $223.27. The timing is crucial. AbbVie continues to push for growth beyond its legacy blockbusters as biosimilar competition…
15 January 2026
··
Pfizer stock rises as CEO bets on “Viagra-like” obesity demand; what investors watch next

Pfizer stock rises as CEO bets on “Viagra-like” obesity demand; what investors watch next

New York, Jan 14, 2026, 19:09 EST — After-hours Shares of Pfizer (PFE.N) climbed Wednesday as investors focused on the company’s move into obesity treatments, now the key battleground in the pharmaceutical sector. The stock closed regular hours roughly 1.7% higher, settling at $25.58. After-hours trading remained subdued. The obesity story is crucial for Pfizer as it seeks to regain…
15 January 2026
··
1 2 3 4 5 6 … 45

Stock Market Today

  • Four Seasons Education (NYSE:FEDU) Shares Tumble 30% Amid Mixed Growth Signals
    January 22, 2026, 6:48 AM EST. Shares of Four Seasons Education (Cayman) Inc. (NYSE:FEDU) have plunged 30% in the past month, continuing a difficult 27% decline over the last year. Despite a seemingly attractive price-to-earnings (P/E) ratio of 13.5x, below the U.S. market average of roughly 20x, the company's uneven earnings growth raises concerns. After a striking 323% earnings per share increase last year, the firm showed no growth across the past three years, suggesting inconsistent performance. This lag behind the broader market's projected 16% expansion likely explains the low P/E and wary investor sentiment. The sharp stock drop reflects caution about the company's future growth prospects, signaling that its current valuation more so captures investor apprehension than undervaluation.
Go toTop